United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - riociguat (unii: ru3fe2y4xi) (riociguat - unii:ru3fe2y4xi) - riociguat .5 mg - adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (cteph), (who group 4) after surgical treatment, or inoperable cteph, to improve exercise capacity and who functional class [see clinical studies (14.1)]. adempas is indicated for the treatment of adults with pulmonary arterial hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening. efficacy was shown in patients on adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids. studies establishing effectiveness included predominately patients with who functional class ii–iii and etiologies of idiopathic or heritable pah (61%) or pah associated with connective tissue diseases (25%) [see clinical studies (14.2)] . based on data from animal reproduction studies, adempas may cause fetal harm when administered to a pregnant woman and is contraindicated in females who are pregnant. adempas was consistently

United States - English - NLM (National Library of Medicine)

meda pharmaceuticals - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 5 mg - demadex is indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. demadex is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with demadex. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure educ

United Kingdom - English - myHealthbox

bayer ag -

New Zealand - English - Ministry for Primary Industries

bayer new zealand limited - bacillus subtilis qst 713 - wettable powder - bacillus subtilis qst 713 1.46 b cfu/g - fungicide - fungicide

Australia - English - Department of Health (Therapeutic Goods Administration)

eisai australia pty ltd - carmustine, quantity: 7.7 mg - implant - excipient ingredients: polifeprosan - gliadel is indicated in newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation. gliadel is also indicated for use as an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme (gbm) for whom surgical resection is indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - adenosine, quantity: 30 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - intravenous adenoscan is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging, in patients unable to exercise adequately.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - adenosine, quantity: 3 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - therapeutic indications: rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory by-pass tracts (wolff-parkinson-white syndrome). diagnostic indications: aid to diagnosis of broad or narrow complex supraventricular tachycardias. although adenocor is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of av conduction helps diagnosis of atrial activity. in this respect adenosine should be used as an adjunct to, but not a replacement for, clinical and ecg observations. it should be only used when, despite all diagnostic attempts, doubt still persists. improved diagnostic sensitivity of intracavity electrophysiological investigations

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 1 mg - tablet, film coated - excipient ingredients: hypromellose; crospovidone; lactose monohydrate; hyprolose; sodium lauryl sulfate; microcrystalline cellulose; magnesium stearate; propylene glycol; titanium dioxide; iron oxide yellow - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 2 mg - tablet, film coated - excipient ingredients: titanium dioxide; hypromellose; sodium lauryl sulfate; hyprolose; magnesium stearate; lactose monohydrate; iron oxide red; iron oxide yellow; microcrystalline cellulose; propylene glycol; crospovidone - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - riociguat, quantity: 1.5 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; propylene glycol; microcrystalline cellulose; hypromellose; magnesium stearate; titanium dioxide; crospovidone; hyprolose; iron oxide yellow - pulmonary arterial hypertension:,adempas, as monotherapy or in combination with approved pah treatments (endothelin receptor antagonists or inhaled or subcutaneous prostanoids), is indicated for the treatment of:,? idiopathic pulmonary arterial hypertension,? heritable pulmonary arterial hypertension,? pulmonary arterial hypertension associated with connective tissue diseases or,? pulmonary arterial hypertension associated with congenital heart disease in adult patients with who functional class ii, lll or iv symptoms,chronic thromboembolic pulmonary hypertension:,adempas is indicated for the treatment of:,persistent or recurrent chronic thromboembolic pulmonary hypertension (cteph) after surgical treatment or,inoperable cteph in adult patients with who functional class ii, lll or iv symptoms